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Abstract: Severe combined immunodeficiency (SCID) can be detected through newborn bloodspot
screening. In the UK, the National Screening Committee (NSC) requires screening programmes to
be cost-effective at standard UK thresholds. To assess the cost-effectiveness of SCID screening for
the NSC, a decision-tree model with lifetable estimates of outcomes was built. Model structure and
parameterisation were informed by systematic review and expert clinical judgment. A public service
perspective was used and lifetime costs and quality-adjusted life years (QALYs) were discounted
at 3.5%. Probabilistic, one-way sensitivity analyses and an exploratory disbenefit analysis for the
identification of non-SCID patients were conducted. Screening for SCID was estimated to result in
an incremental cost-effectiveness ratio (ICER) of £18,222 with a reduction in SCID mortality from
8.1 (5–12) to 1.7 (0.6–4.0) cases per year of screening. Results were sensitive to a number of parameters,
including the cost of the screening test, the incidence of SCID and the disbenefit to the healthy at birth
and false-positive cases. Screening for SCID is likely to be cost-effective at £20,000 per QALY, key
uncertainties relate to the impact on false positives and the impact on the identification of children
with non-SCID T Cell lymphopenia.
Keywords: severe combined immunodeficiency; SCID; cost-effectiveness; economic; newborn
screening; neonatal screening
1. Introduction
Screening newborns for severe combined immunodeficiency (SCID) using T-cell receptor excision
circles (TRECs) on the blood spot was added to the core US Recommended Uniform Screening Panel
in 2010 [1]. Whilst SCID screening has now been implemented in all US states, take up has been
slower internationally, with a number of European countries conducting pilots [2,3]. Within the UK,
the National Screening Committee (NSC) advises government and the National Health Service (NHS)
concerning what newborn screening tests should be offered. This advice is based on independent
assessments of the evidence of the potential benefits, harms and cost-effectiveness of each screening
test [4].
There is strong evidence that diagnosis of SCID prior to symptomatic presentation improves the
survival chances of SCID patients [5–9]. There is also evidence that earlier diagnosis substantially
reduces the cost of treating SCID through reduced infection rates and subsequent hospitalisations [10,11].
Five economic analyses of SCID screening also suggest that screening may be cost-effective in the US,
New Zealand and the Netherlands [12–16]. As there are differences between countries in terms of
treatment costs and benefits and how health interventions are assessed, a UK-specific cost-effectiveness
model was developed.
The cost-effectiveness study reported here was undertaken on behalf of the UK NSC, to inform its
consideration of screening for SCID within the NHS Newborn Blood Spot Screening Programme [4].
The study incorporates UK data on incidence and current practice for SCID treatment in the UK
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together with quality of life estimates. The study uses economic threshold analyses to examine the
robustness of the results to the potential disbenefit of the high false-positive rate of the TREC test and
the incidental identification of non-SCID T Cell lymphopenia (TCL) conditions.
2. Materials and Methods
A decision-tree cost-effectiveness model was developed to estimate the cost-effectiveness of
including the additional TREC screening test for SCID in the NHS Newborn Blood Spot Screening
Programme. A cost-effectiveness model provides the framework to enable evidence from a number of
sources to be used together to estimate the total costs and health benefits for both the existing SCID
pathway and for the pathway with the inclusion of newborn screening. The results of the model
can be used to estimate the value of a new intervention, such as screening, using the incremental
cost-effectiveness ratio (ICER).
The decision-tree model used is shown in Figure 1. Following a positive TREC screening test,
patients undergo flow cytometry testing in order to confirm a diagnosis of SCID. Other clinical factors
and genetic testing are used to differentiate the non-SCID TCL cases also identified by screening. Due
to limitations in the evidence, and the focus on SCID patients, only the incremental costs associated
with being identified via screening rather than symptomatically were included for the non-SCID TCL
group. There are, therefore, no costs associated with non-SCID TCL patients in the no-screen arm. Life
tables were used to estimate lifetime costs and health outcomes measured in terms of quality-adjusted
life years (QALYs). The model takes an NHS and Personal Social Services perspective; costs were
estimated at 2014/15 rates and costs and benefits were discounted at 3.5%. The annual number of births
for the UK were estimated from the average of 10 years, 2005–2015 [17–19].
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Figure 1. Model diagram. The figure represents the patient pathway in the screened and no-screened
arm of the model. Some arms are clones of other arms; however, different parameter values are used in
individual arms.
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Patients with SCID identified through screening or those diagnosed early due to a family history
in the no-screen arm are assumed to undergo early haematopoietic stem cell transplantation (HSCT),
or in the case of Adenosine deaminase SCID (ADA-SCID), gene therapy, and have improved outcomes
compared to those diagnosed and treated later due to symptomatic presentation [5–9].
Based upon the 82 cases referred to the two specialist SCID treatment centres in the UK between
2008 and 2012, a UK incidence of 1 in 43,600 (95% Confidence Interval (CI) 1:74,000, 1:29,000) was
estimated. This includes a subjective estimate that around 1.5 patients with SCID may die annually
before they are diagnosed. Based on the UK experience, 30% of patients were assumed to be diagnosed
early due to a family history and 17% are assumed to have ADA-type SCID [20]. A full list of model
parameters is given in Table 1.
Table 1. Parameters table.
Parameter Mean (95% Confidence Interval) Reference
Number of births (UK) 780,835 [17–19]
Incidence of SCID 1:49,000 (1:39,857, 1:61,527) [20]
Incidence of undiagnosed SCID 1:521,000 (1:167,052, 1:7,236,800) [20]
Incidence of syndromes 1:45,000 (1:24,390, 1:110,606) [21]
Incidence of secondary conditions 1:130,000 (1:50,686, 1:782,506) [21]
Incidence of idiopathic TCL 1:99,000 (1:42,255, 1:432,482) [21]
Incidence of positive TREC in pre-terms 1:99,000 (1:42,255, 1:432,482) [21]
Presumptive positives (20 copies/µL) 0.041% (0.0035%, 0.1018%) [22]
Sensitivity for SCID 0.99 (0.985, 0.998) [23]
Proportion of SCID patients with a family history 0.30 (0.21, 0.41) [20]
Proportion of SCID that is ADA-SCID 0.17 (0.1, 0.26) [20]
Proportion of SCID patients with a matched family donor
available
0.25 (0.07, 0.5) [20]
Pre HSCT mortality (late diagnosed) 35.3% (22.8%, 49.3%) [6]
Pre HSCT mortality (early diagnosed) 1.68% (0.11%, 7.63%) [6]
HSCT mortality (late diagnosed) 38.7% (22.4% 56.3%) [6]
HSCT mortality (early diagnosed) 8.48% (1.79%, 23.4%) [6]
Number of days HSCT 54.0 [24]
Early diagnosis—Total days non-critical care 82.6 (50.3, 122.8) [24]
Early diagnosis—Total days critical care 3.96 (0.15, 8.41) [24]
Late diagnosis—Total days non-critical care 144 (108.6, 184.3) [24]
Late diagnosis—Total days critical care 8.19 (3.72, 14.4) [24]
QALYs—early diagnosis (1979–2015 cohort, base case values) 0.95 [25]
QALYs—late diagnosis (1979–2015 cohort, base case values) 0.82 [25]
QALYs—early diagnosis (2000–2015 cohort) 0.96 [25]
QALYs—late diagnosis (2000–2015 cohort) 0.87 [25]
Cost HSCT (early diagnosed) £128,363 [24,26]
Cost HSCT (late diagnosed) £231,186 [24,26]
Cost death prior to HSCT £43,368 [24,26]
Presumptive positive cost £276 [24,26]
Diagnosis SCID £711 [26,27]
Diagnosis idiopathic SCID and syndromes £1,551 [26,27]
Idiopathic SCID follow up (5 years discounted) £20,142 [26,28–30]
Syndromes 4 year follow up £4,872 [24,26]
Follow up preterm & secondary to other conditions £533 [24,26]
UK—United Kingdom; SCID—severe combined immunodeficiency disorder; TCL—T Cell lymphopenia; TREC—T
cell receptor excision circle; ADA—adenosine deaminase deficiency; HSCT—hematopoietic stem cell transplantation;
QALYs—quality-adjusted life years.
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A systematic search [31] identified five studies reporting on the comparative effectiveness of early
vs late transplant [6–9,32]. The Brown et al. study [6] was selected as it is a UK-based study and was
the only study to provide both pre- and post-HSCT mortality estimates. The model assumes that all
deaths occur in the transplantation year and that surviving patients have a normal life expectancy.
Patients with ADA-SCID have additional treatment options including enzyme replacement therapy
prior to transplant and gene therapy for those with a non-matched donor [33]. ADA-SCID-specific
parameters are given in Tables S1 and S2.
The baseline analysis assumed a cut-off of 20 copies/µL for the TREC screening test, with a
presumptive positive rate of 0.04%, resulting in an estimated 312 referrals to flow cytometry per
year [22]. Data from the Californian screening programme was used to estimate the incidence of
non-SCID TCL conditions identified at screening due to the relatively low cut-off values used and the
large number of births compared to other states [21,34]. Given that the estimated UK presumptive
positive rate is higher than in California, it was assumed that the UK would have a higher proportion
of cases being classed as false-positive rather than a higher incidence of other non-SCID T-cell
lymphopenia [21,22].
While studies have demonstrated the TREC test to have perfect sensitivity at the expected TREC
cut off [23], a sensitivity of 0.99 was used in the model to take into account the potential for false
negatives in a population-based screening programme. The positive predictive value of the TREC test
for SCID was estimated at 5.3%.
The cost of the screening test kit is estimated at £3.50. The additional labour for the TREC test
was estimated based on expert opinion to be 0.5 full-time equivalent of NHS grade-5 members of
staff per each of the 13 laboratories, to give an additional cost of £166,000 per year, and equipping the
laboratories was estimated at £35,000 excluding installation costs [35].
The patient pathway following a positive TREC test is shown in Figure 2. It is assumed that the
flow cytometry test is able to differentiate healthy false-positive patients, SCID patients and some
of the different TCL conditions. Markers such as physical features and the presence of other severe
health problems can further differentiate non-SCID TCL patients [36]. Genetic tests differ depending
on suspected conditions [27]. Only the incremental costs associated with being detected via screening,
such as immunology appointments, are applied to the non-SCID TCL group. Longer follow-up costs
are included where screening enables an earlier diagnosis, such as in the syndromes group, or where
patients may not have presented symptomatically, such as the idiopathic TCL group. As some of
the non-SCID patients are likely to be diagnosed at birth, these assumptions may overestimate the
incremental costs.
Data on length of stay for patients diagnosed early and late was based upon current practice in one
of the two UK SCID centres [24]. As shown in Table 1, the number of inpatients days were substantially
reduced for those with a SCID diagnosis at birth compared to those with a later diagnosis. Total
inpatient cost of HSCTwas calculated fromNHS reference costs [26] for elective and non-elective HSCT
adjusted for the SCID specific length of stay. The Great Ormond Street Hospital (GOSH) data include
readmittances and is assumed to include complications following transplants, such as additional
transplants and graft versus host disease (GvHD), but does not include the length of stay at other
hospitals before the patients were referred to GOSH. Full costing details, including the costs of longer
term treatments such as immunoglobulin, are given in the Table S1 in the Supplementary Material [28].
No studies were identified that report health-related quality of life utilities in SCID patients.
To estimate quality of life, a clinician mapped information from a database of 78 UK SCID patients,
transplanted between 1979–2015, onto the EuroQol 5-dimensions 3-level (EQ-5D-3L) health state
descriptions [37,38]. The EQ-5D-3L time trade-off valuations were applied to the health state profiles
to derive health utility estimates. The average health state utility for the 27 patients diagnosed at birth
was 0.96 (sd 0.09) compared to 0.82 (sd 0.25) for the 51 later diagnosed patients. Figure 3 shows the
cumulative distribution of the EQ-5D scores and the QALY dimension are shown in the Figure S1
in the Supplementary Material. Treatment for SCID has improved over the time period included, in
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order to explore this affect, only EQ-5D-3L estimates for patients between 2000–2015 were used in a
sensitivity analysis.
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Figure 2. Screened patient pathway. The figure represents the pathway for all screened patients and
includes the test and appointments for all non-SCID diagnosed patients.
 






       
&X
PX
ODW
LYH
SU
RS
RUW
LRQ

(4'8WLOLW\
'LDJQRVHGODWHUFRKRUW 'LDJQRVHGDWELUWKFRKRUW
Figure 3. Cumulative distribution of EuroQol 5-dimensions (EQ-5D) utility scores for the
diagnosed-at-birth cohort and the diagnosed later cohort. The red square line represents cumulative
distribution of EQ-ED scores for the 27 patients in the diagnosed-at-birth cohort from Great Ormond
Street Hospital. The blue diamond line represents the cumulative distribution of EQ-5D scores for the
51 patients in the diagnosed later than birth cohort.
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The systematic search [31] identified six studies that reported long-term clinical outcomes for
SCID patients undergoing HSCT [7,39–43]. While it was not possible to synthesise the data; certain
outcomes, such as the proportion of patients classified as healthy, low-weight, and developmental
delay, were consistently different in the early vs late transplanted cohorts [7,42,43]. It is assumed that
ADA-SCID patients undergoing either HSCT or gene therapy have the same long-term outcomes as
general SCID patients. Full details of the long-term outcomes including costs are provided in Tables S1
and S3 in the Supplementary Material.
Parametric distributions were used to characterise parameters in the model, see Table S2 in the
Supplementary Material, and 10,000 replicates were used to estimate uncertainty around the results.
A number of one-way sensitivity analyses were also conducted. These included halving and doubling
the incidence rate. Increasing the TREC cut-off rate to 30 copies/µL, with the increased presumptive
positive cases assumed to be additional false-positive cases in the first instance and a proportional
increase in the non-SCID TCL cases in the second. Increasing the cut-off rate does not change the
sensitivity of the TREC screening test as in the Adam et al. [22] study no SCID cases had a level of
about 15 copies/µL. However, a higher cut-off may be considered, at least initially, to comply with
manufacturer’s recommendations or to ensure the sensitivity found in smaller studies is maintained in
a nationwide screening programme [3]. The proportion of SCID patients identified due to a family
history in the no-screen armwas varied, as was the cost of the screening test. To explore the uncertainty
around the mortality estimates, two analyses were run that varied the odds ratio of the pre- and
post-transplant mortality rates. The discount rate for public health intervention of 1.5% for both costs
and benefits was used [44] and a discount rate of 3.5% for costs and 1.5% for benefits based on the
NICE guidance for a sensitivity analysis were also conducted [45].
An expected value of perfect information (EVPI) analysis was undertaken using the Sheffield
Accelerated Value of Information (SAVI) programme [46]. EVPI calculates the value of eliminating all
uncertainty in the model and parameter EVPI identifies the value of eliminating uncertainty in each
individual parameter.
In order to explore the potential economic impact on those with a false-positive TREC test result
and the impact of diagnosing otherwise healthy infants with non-SCID TCL, a threshold analysis was
conducted. This analysis calculates the minimum per person health-related utility decrement that
would cause the overall cost effectiveness of screening to increase above the thresholds of £20,000 and
£30,000 per QALY. Based on the Californian screening programme, it was assumed that 33% (7 out
of 21) of the non-SCID TCL would be healthy at birth and, therefore, included in the analysis [34].
3. Results
The base case results are shown in Table 2. The cost per QALY gained is estimated at £18,222
(£12,013, £27,763). The probability that screening is considered cost-effective is 65% and 99% at the
£20,0000 and £30,000 per QALY thresholds, respectively. Overall uncertainty is presented in the
cost-effectiveness plane shown in Figure 4. Cost associated with the immediate treatment and HSCT
are lower in the screened arm; however, the long-term follow-up and management costs are higher
than in the no-screen arm. While the per patient costs are lower, and the rates of complications are
either the same or lower in the screened arm, the increase in survival increases the number of patients
experiencing both complications and the general follow-up costs leading to overall higher costs.
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Table 2. Results.
Screening 95% CI No Screening 95% CI Incremental 95% CI
Outcomes
SCID cases diagnosed
symptomatically
0.2 (0.1, 0.3) 11.0 (8.4, 14.1) −10.9 (−13.9, −8.2)
SCID cases diagnosed
via a family history
0 (0, 0) 4.9 (3.1, 7.0) −4.9 (−3.1, −7.0)
SCID cases not
diagnosed
0 (0, 0) 1.5 (0.1, 4.8) −1.5 (−0.1, −4.8)
SCID cases screen
detected
17.2 (13.5, 21.7) 0 (0, 0) 17.2 (13.5, 21.7)
ADA SCID 2.9 (1.6, 4.7) 2.9 (1.6, 4.7) 0 (0.0, 0.0)
SCID mortality 1.7 (0.6, 4.0) 8.1 (5.3, 12.0) −6.3 (−9.7, −4)
Screening
outcomes
Non SCID TCL 31.1 (16.3, 50.1) 0 (0, 0) 31 (16.3, 50.1)
Pre-term 8.0 (1.9, 18.7) 0 (0, 0) 8 (1.9, 18.7)
Total presumptive
positives
322.1 (79.5, 852.9) 0 (0, 0) 0 (79.5, 852.9)
Costs Direct screening costs £3.04 m (£2.97 m, £3.19 m) £0.00 m (£0.00 m, £0.00 m) £3.04 m (£2.97 m, £3.19 m)
Diagnosis and follow
up pre-terms
£4,394
(£1,029.36,
£10,311)
£0 (£0.00 m, £0.00 m) £4,394 (£1,029.36, £10,311)
Diagnosis and follow
up non SCID TCL
£0.27 m (£0.12 m, £0.51 m) £0.00 m (£0.00 m, £0.00 m) £0.27 m (£0.12 m, £0.51 m)
Diagnosis costs SCID £14,235 (£11,112, £17,967) £13,023 (£13,023, £15,954) £1,212 (£61.7, £3,919)
SCID treatment up
and including HSCT
£3.35 m (£2.20 m, £4.83 m) £3.63 m (£3.63 m, £2.65 m) −£0.28 m (−£1.10 m, £0.62 m)
SCID long-term costs £2.03 m (£1.20 m, £3.12 m) £1.30 m (£1.30 m, £0.78 m) £0.72 m (£0.23 m, £1.37 m)
Totals Total costs £7.30 m (£5.96 m, £9.06 m) £3.96 m (£3.96 m, £2.92 m) £3.34 m (£2.36 m, £4.47 m)
Total QALYs 410.1 (308.3, 527.3) 226.9 (226.9, 164.9) 183.17 (109.3, 267.2)
ICER £18,222 (£12,013, £27,763)
CI—Confidence Interval; SCID—Severe Combined Immunodeficiency; ADASCID—adenosine deaminase deficiency
SCID; TCL—T-cell immunodeficiency; HSCT—hematopoietic stem cell transplant; QALYs—Quality-adjusted life
years; ICER—Incremental cost effectiveness ratio.
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Figure 4. Cost-effectiveness plane. Each blue cross represents an individual model run. The red
square represents the incremental cost-effectiveness ratio (ICER). The dotted line the £20,000 per quality
adjusted life year (QALY) threshold hold and the solid line the £30,000 per QALY threshold.
Table 3 presents the sensitivity analysis results. The results indicate that the cost-effectiveness is
substantially improved by a reduction in the TREC test cost, an increase in incidence, and the use of
other discount rates. The results are also sensitive to the TREC cut-off and the proportion of SCID
that is currently detected by a family history. Increasing the TREC cut-off reduces the probability that
screening is cost-effective, from 65% to 58%, at £20,000 per QALY but only marginally, from 99% to
98%, at £30,000 per QALY. However, the impact on the substantial increase in false-positive cases, up
from 266 in the base case to 880, and any arising disbenefit would need to be considered carefully. In
terms of the mortality rates for the ICER to go above £20,000 or £30,000 per QALY, the pre-transplant
mortality rate in the early diagnosed cohort would need to increase to 10% or 28%, respectively. For
the transplant mortality rate, the mortality rate would need to increase to 17% and 36%, respectively,
in the early diagnosed cohort.
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Table 3. Sensitivity analyses results.
Sensitivity
Analysis
Screening No Screening Incremental
Probability
Cost-Effective at
Threshold
Costs QALYs Costs QALYs Costs QALYs ICER £20k £30k
Base case £7.30m 410 £3.96m 227 £3.34m 183 £18,222 65% 99%
Incidence
Halved £5.49m 223 £2.01m 113 £3.48m 110 £31,647 2% 35%
Doubled £10.97m 785 £7.89m 453 £3.07m 332 £9,266 100% 100%
TREC cut off
Additional false
positives
£7.53m 412 £3.99m 227 £3.54m 185 £19,137 56% 98%
Increase
proportionately
£7.44m 409 £3.98m 227 £3.46m 182 £18,983 56% 98%
Family History
10% family history £7.32m 411 £4.06m 183 £3.26m 229 £14,237 95% 100%
50% family history £7.30m 410 £3.89m 269 £3.42m 141 £24,208 14% 84%
Test cost
£1.50 £5.75m 410 £3.98m 227 £1.77m 183 £9,674 100% 100%
£2.50 £6.55m 413 £3.99m 228 £2.56m 184 £13,876 95% 100%
£4.50 £8.10m 410 £3.98m 227 £4.11m 183 £22,471 25% 92%
Discount rate
1.5% both costs
and health benefits
£8.82m 702 £5.02m 391 £3.80m 311 £12,219 99% 100%
1.5% health
benefits & 3.5%
costs
£7.32m 703 £4.00m 392 £3.32m 311 £10,680 100% 100%
QALYs
2000–2015 cohort
QALYs used
£7.32m 415 £3.98m 235 £3.34m 180 £18,588 61% 98%
Pre-transplant
mortality
Early diagnosed
mortality (OR)
8.15%(0.23) £7.12m 381 £3.67m 206 £3.45m 175 £19,691 51% 97%
29.40%(0.83) £6.44m 294 £3.48m 182 £2.95m 113 £26,237 12% 68%
Post-transplant
mortality
Early diagnosed
mortality (OR)
17.42%(0.45) £7.16m 369 £3.68m 203 £3.48m 166 £20,915 39% 96%
36.77%(0.95) £6.79m 283 £3.58m 178 £3.21m 105 £30,746 3% 43%
QALYs—Quality-adjusted life years; 20k—£20,000; 30k—£30,000; m—million; TREC—T-cell receptor excision circles;
OR—odds ratio.
The overall EVPI per person affected by the decision is estimated at £0.15 per person. Assuming
an annual number of births affected by the decision of 780,835 and a decision horizon of five years, the
overall expected value of removing decision uncertainty for the UK is estimated at £595,900. Research
or data collection exercises costing more than this amount would not be considered a cost-effective use
of resources. The single-parameter EVPI (EVPPI) demonstrates that the key uncertainties in the model
relate to the underlying incidence of SCID in the population (EVPPI of around £80,000) and the cost of
early transplantation, specifically the length of stay in non-critical care (around £65,000). The second
largest group of parameters relate to the relative survival benefit from early versus late transplantation
and the proportion detected due to a family history (all under £20,000).
The model estimates that there will be, on average, 266 (24,796) false positives and 31 (16, 50)
babies identified each year with non-SCID TCL conditions, excluding pre-terms. It is estimated that
eight of non-SCID TCL cases would present as healthy at birth and would not be diagnosed at this
stage in the absence of screening [34]. This group is likely to include patients with ataxia telangiectasia
and idiopathic TCL.
The results exploratory threshold analysis, shown in Table 4, calculates the minimum quality
of life decrement that would need to be applied to each healthy-at-birth non-SCID TCL patient and
false-positive case in order to increase the ICER over the cost-effectiveness threshold of £20,000 or
£30,000 per QALY. As an example to aid interpretation, with a cost per TREC test of £3.50, if eight
healthy-at-birth children had, on average, a disbenefit of one QALYs lost as a result of being identified
with idiopathic TCL through screening, we would have to assume that each of the 260 false-positive
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infants also suffered a disbenefit of over six quality-adjusted days in order for the cost-effectiveness
of screening to go over a £20,000 threshold with discounting at 3.5%. The results for the separate
false-positive and non-SCID TCL analyses are shown in Table S4 in the Supplementary Material.
Table 4. Threshold results.
Healthy at Birth Disbenefit
(QALY)
Cost per TREC Test £3.50
False-Positive Disbenefit Threshold (Quality-Adjusted Days)
Discounting 3.5% Discounting 1.5%
Mean (95% CI) Mean (95% CI)
0 17 (0, 22) 171 (1,113, 91)
1 6 (0, 14) 159 (1,069,83)
2 0 (0, 6) 148 (1,025, 75)
3 0 (0, 0) 136 (980, 67)
4 0 (0, 0) 125 (936, 59)
10 0 (0, 0) 55 (672, 11)
20 0 (0, 0) 0 (230, 0)
TREC—T-cell receptor excision circles; QALYs—Quality-adjusted life years, CI—Confidence interval.
4. Discussion
This CEA of SCID screening is the first to include QALY estimates based on SCID patients,
UK-specific data from the two UK SCID treatment centres, and an EVPI analysis and is the first to
attempt to quantify the impact on non-SCID patients. The model estimated that screening for SCID in
the UK would identify 17 (14, 22) newborns with SCID annually, prevent 6.3 (4.0, 9.7) SCID-related
deaths with a total gain of 184 (118, 274) discounted QALYs. Screening will increase total discounted
lifetime costs by an estimated £3.3 (£2.4, £4.5) million per year. The ICER for SCID screening is
£18,222 per QALY gained, with 65% and 99% probability of this being considered cost-effectiveness
at a threshold of £20,000 and £30,000 respectively. The results are in line with previously published
cost-effectiveness studies that used QALYs [14,16].
The EVPI analysis estimates the value of future research and key uncertainties. Further data
collection could be used to improve the data on incidence, mortality rates, length of hospital stay and
proportion detected by a family history but given the small number of SCID patients diagnosed in the
UK each year, there is still likely to be uncertainty in these estimates. One-way sensitivity analyses
were conducted on these parameters to explore how robust the results are to changes in the parameter
values. A change in the mortality rates does affect the probability that screening is cost-effective.
However, assuming only a very small survival benefit at pre- or post-transplant (5.5% and 2.2%) for
those early diagnosed, there is a still a 68% and 43% probability that screening is cost-effective at a
£30,000 threshold. Parameters were also compared to data from other countries, for example, the
GOSH length of stay data used is comparable to US and French studies [10,11].
The mortality estimates were taken from retrospective studies which may not reflect current
outcomes [6]. Survival rates, especially for those diagnosed late, are likely to have improved over time
due to a raised awareness of SCID and better supportive care [47]. They also may not reflect wider
current practice, for example, in the UK rotavirus, a live vaccination, has been given at 8 weeks of age
since 2013 and causes severe problems in SCID patients [48]. These impacts will not have been fully
captured in the retrospective survival and outcomes estimates used.
There are other uncertainties and factors that may not have been fully captured in the EVPI but
may still affect the decision. These include the impact on false-positive and non-SCID TCL cases, the
quality-of-life estimates, and choices on the cost of the test and the discount rate used. Sensitivity
Int. J. Neonatal Screen. 2019, 5, 28 10 of 15
analyses showed that the cost of the test and the choice of discount rate had a sizeable impact on the
ICER, with the probability that screening is cost-effective at £20,000 increasing from 65% to 95% when
the cost of the TREC test is reduced from £3.50 to £2.50.
There is a lack of quality-of-life utility values that could be used for those with a false-positive or
non-SCID TCL result. Whilst screening for untreatable conditions is generally not recommended, the
majority of the non-SCID TCL cases identified are likely to present symptomatically without screening
at or soon after birth [34]. It is assumed that for these patients, the marginal impact of the screening
results is negligible. Earlier diagnosis in TCL-related conditions, for instance, Ataxia-Telangiectasia,
has potential benefits and disbenefits for patients and families, with potentially ambiguous impacts on
quality of life. Benefits may include a simplified diagnosis pathway, earlier provision of supportive
treatments and allow families to prepare both practically and emotionally for the future. Conversely,
in the case of conditions such as Ataxia-Telangiectaisa, earlier diagnosis may lead to premature
medicalisation, with attendant stress and anxiety, together with the loss of a normal childhood [49–52].
The evidence from the Californian screening programme and the wider US shows some benefit
from screening in non-SCID TCL patients. In California, of the 63 cases diagnosed with a syndrome,
16% received immune-directed treatments. Of the 47 cases of DiGeorge Syndrome, 9% received a
thymus transplant while the other 90% had partial DiGeorge syndrome with improving T cell function
over time [21]. In a separate study of patients diagnosed with 22q11.2 Deletion Syndrome, the most
common cause of DiGeorge, 45% of patients were diagnosed prior to the screening result [53]. These
results show that there may be some benefit to patients who would not have been diagnosed either
symptomatically or through a family history prior to the TREC screening result. The inclusion of this
benefit would improve the probability that SCID screening is cost-effective. However, more research,
which includes a comparison with non-screen detected cases, is needed to fully quantify the potential
impact on these patients.
The greatest impact is likely to be on those defined as idiopathic TCL. The experience of this in
California is thatwhile somewill resolve spontaneously, otherswill remainwithout a firmdiagnosis [54].
The uncertainty in this diagnosis and potential for unnecessary medicalisation mean that there is likely
to be an impact on the quality of life [52]. This study includes the first attempt to quantify the potential
impact to those with a false-positive result and those who would be otherwise healthy-at-birth infants.
The impact on these patients was raised as an issue in the Van der Ploeg study [16]. The threshold
analysis calculates the number of quality-adjusted days that would need to be lost in order for the ICER
to go above £20,000 or £30,000 per QALY. The disbenefit would have to be relatively large, in the order
of one QALYs per healthy-at-birth non-SCID TCL and six quality-adjusted days per false-positive case.
There is also an absence of quality-of-life utility evidence in the SCID population. This
methodological weakness is not specific to SCID, but rather arises primarily from deeper foundational,
if not philosophical, controversies associated with undertaking economic evaluation in child health [55].
Whilst there have been recent developments with the CHU9D and the paediatric EQ-5D-Y [56], there
are currently no paediatric value sets available. In the absence of such measures, this study has used
an adult EQ-5D valuation applied to health state descriptions generated with reference to medical
records of affected children. This is the first attempt to measure the quality of life of SCID patients
using a utility instrument without using proxy conditions. Whilst there are undoubted methodological
weaknesses in this approach, there is no evidence to suggest a structural bias in the estimates obtained.
An additional factor that is not included in this analysis is the current timing of live vaccinations
such as BCG and rotavirus. If live vaccinations are given before the screening results are known,
then the benefits from screening may be reduced [57]. In the UK, it is recommended that the BCG
vaccination should be given to high-risk infants or to all those born in areas with a TB incidence
of over 40 in 100,000 on the neonatal ward [58]. The model assumes that no live vaccinations are
given prior to the newborn screening results. However, the impact of changing the BCG vaccination
recommendations has not been considered within this analysis.
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In 2016–2017, the UK NSC considered the establishment of SCID screening within the NHS Blood
Spot Screening Programme. The economic study reported here comprised part of the evidence base
considered by the Committee in forming its advice to ministers to evaluate SCID screening within a
pilot study. The purpose of this evaluation being to address many of the uncertainties identified in this
analysis including, the number of families with healthy babies who might be told they are ill when
they are not (false positives), what care and treatment to offer babies with other causes of low numbers
of white cells, how many babies are born have a prior family history and how the laboratory and
treatment services will cope with the additional workload [59]. Following the completion of the pilot,
the Committee will consider again whether SCID screening should be part of the wider Programme.
5. Conclusions
Screening for SCID is likely to be cost-effective at £20,000 per QALY, and is robust to changes to
model parameters, key uncertainties relate to the impact of false positives and the identification of
children with non-SCID TCL.
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